Nabriva - Strong Potential 💪
-Nabriva Therapeutics (NASDAQ:NBRV) and Sinovant Sciences' antibiotic lefamulin was non-inferior to moxifloxacin in a phase 3 study, according to top-line results.
-In a modified intent to treat (mITT) population, the clinical response success rates were 76.8% for lefamulin and 71.4% for moxifloxacin.
-Also, Sinovant inked an agreement with a Chinese subsidiary of Sumitomo Dainippon Pharma (OTCPK:DNPUF) to acquire development and commercialization rights for lefamulin in Greater China. Nabriva shares are up 40.5% to $2.08 in after-hours trading.
-In a modified intent to treat (mITT) population, the clinical response success rates were 76.8% for lefamulin and 71.4% for moxifloxacin.
-Also, Sinovant inked an agreement with a Chinese subsidiary of Sumitomo Dainippon Pharma (OTCPK:DNPUF) to acquire development and commercialization rights for lefamulin in Greater China. Nabriva shares are up 40.5% to $2.08 in after-hours trading.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.